Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04633005 · ClinicalTrials.gov registry record · Phase 2
Polypill Strategy for Heart Failure With Reduced Ejection Fraction
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT04633005 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 212 participants.
The verdict
NCT04633005, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of low socioeconomic status (SES). Although effective therapies exist, gaps in their uptake contribute substantially to the excess burden of heart failure. The "polypill" is an inexpensive once daily pill containing three agents proven to improve morbidity and mortality in heart failure and represents potential strategy for increasing the utilization of proven HF therapies. The proposed study is a pragmatic, single-center, randomized trial to test the feasibility and effectiveness of a polypill-based strategy for the treatment of HFrEF in a low-income, racially diverse population.
Interventions
- DRUG Polypill
- DRUG Control Rx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04633005
The ClinicalTrials.gov registry entry for NCT04633005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Polypill is the first listed.
NCT04633005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04633005 about?
NCT04633005 is a clinical study titled "Polypill Strategy for Heart Failure With Reduced Ejection Fraction". Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of low socioeconomic status (SES). Although effective therapies exist, gaps...
What is the current status of trial NCT04633005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2021-11-15. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT04633005?
The interventions under investigation include: Polypill (DRUG), Control Rx (DRUG).
Who is sponsoring clinical trial NCT04633005?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.